开发用于膜蛋白降解的因特林辅助双特异性阿帕特马基默体
Weidi Sun1,2, Hui Zhang2,3, Wanlin Xie2
1Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Province, Hunan University, Changsha, Hunan 410082, China.
Journal of the American Chemical Society
|September 3, 2024
概括
lysosome-targeting chimeras (LYTACs) 提供了一种降解膜蛋白的新方法. 研究人员开发了因整蛋白α3β1 (ITGA3B1) 促成的双特异性体仿真体 (ITGBACs),用于改善蛋白质降解和癌症治疗.
科学领域:
- 生物化学
- 分子生物学
- 药物发现
背景情况:
- lysosome-targeting 嵌合体 (LYTAC) 是通过 lysosomal 途径降解膜蛋白的一个有希望的策略.
- 细胞系中 lysosome-targeting受体 (LTR) 的可变表达限制了 LYTAC 的广泛适用性.
- 针对特定的膜蛋白对于疾病干预和治疗至关重要.
研究的目的:
- 开发一种新的膜蛋白降解平台,克服现有LYTAC的局限性.
- 创建整合蛋白α3β1 (ITGA3B1) 促进的双特异性合体仿真体 (ITGBACs),以增强 lysosomal 向.
- 评估ITGBACs在降解病变膜蛋白和抑制瘤生长方面的有效性.
主要方法:
- 设计和合成针对ITGA3B1和特定膜蛋白的双特异性合体 (ITGBAC).
- 在体外评估ITGBACs诱导CD71和PTK7等标蛋白质的降解能力.
- 在携带瘤的小鼠模型中评估ITGBAC的治疗效果,包括瘤生长抑制.
主要成果:
- 它有效地促进了病态膜蛋白的降解 (CD71,PTK7).
- 目标蛋白质的降解诱导了癌细胞的显著细胞循环停止和细胞亡.
- 在临床前小鼠模型中,ITGBAC显著抑制瘤生长.
结论:
- ITGBACs代表了针对膜蛋白降解的新和多功能平台.
- 这种方法提供了利用瘤特异性LTR用于向癌症治疗的有希望的治疗策略.
- 在疾病干预和治疗方面,ITGBAC平台具有广泛的应用潜力.
相关概念视频
Tagging and Fusion Proteins
6.6K
Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
6.6K
Tail-anchoring of Proteins in the ER Membrane
3.1K
Tail-anchored, or TA, proteins are estimated to make up to 3-5% of membrane proteins found in the eukaryotic cell. Such proteins have a single transmembrane domain located approximately 30 amino acid residues upstream from the C-terminal end. As a result, the signal recognition particle (SRP) cannot guide a TA protein to the ER membrane for cotranslational insertion. Hence, they are integrated into the ER membrane post-translationally using their C-terminal end as the anchor. TA proteins...
3.1K


